Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells

United European Gastroenterology Journal

Volumn 5, Issue 8, 2017, Pages 1108-1115

  Gigli, Stefano ^a   Seguella, Luisa ^a   Pesce, Marcella ^b   Bruzzese, Eugenia ^b   D’Alessandro, Alessandra ^b   Cuomo, Rosario ^b   Steardo, Luca ^a   Sarnelli, Giovanni ^b   Esposito, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

cannabidiol; cannabinoids; Clostridium difficile; clostridium difficile toxin A; intestinal permeability

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR ANTAGONIST; CLOSTRIDIUM DIFFICILE TOXIN A; GUANOSINE TRIPHOSPHATE; OCCLUDIN; PROTEIN BAX; PROTEIN ZO1;

APOPTOSIS; ARTICLE; CACO-2 CELL LINE; CELL VIABILITY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; INTESTINE MUCOSA; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 85037033439     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640617698622     Document Type: Article

References (35)

1. McFarland LV, Surawicz CM, Rubin M, Recurrent Clostridium difficile disease: Epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43–50.
2. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: New developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526–536.
3. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015; 372: 1539–1548.
4. Voth DE, Ballard JD, Studi D, Clostridium difficile toxins: Mechanism of action and role in disease. Clin Microbiol Rev 2005; 18: 247–263.
5. Sun X, Savidge T, Feng H. The enterotoxicity of Clostridium difficile toxins. Toxins 2010; 2: 1848–80.
6. Kelly CP, Lamont JT. Clostridium difficile infection. Annu Rev Med 1998; 49: 375–390.
7. Borrelli F, Aviello G, Romano B, Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 2009; 87: 1111–1121.
8. De Filippis D, Esposito G, Cirillo C, Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PloS One 2011; 6: e28159–e28159.
9. Izzo A, Sharkey K. Cannabinoids and the gut: New developments and emerging concepts. Pharmacol Ther 2010; 126: 21–38.
10. O’Sullivan SE, Kendall D. Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611–616.
11. Mishima K, Hayakawa K, Abe K, Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. Stroke 2005; 36: 1077–1082.
12. Hampson AJ, Grimaldi M, Axelrod J, Cannabidiol and (-)D9-tetrahydrocannabinol are neuroprotective antioxidants. PNAS 1998; 95: 8268–8273.
13. Laprairie RB, Bagher AM, Kelly ME, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Brit J Pharmacol 2015; 172: 4790–4805
14. Alhamoruni A, Lee AC, Wright KL, Pharmacological effects of cannabinoids on the Caco-2 Cell culture model of intestinal permeability. J Pharmacol Exp Ther 2010; 335: 92–102.
15. Alhamoruni A, Wright KL, Larvin M, Cannabinoids mediate opposing effects on inflammation-induced intestinal permeability. Brit J Pharmacol 2012; 165: 2598–2610.
16. Esposito G, Nobile N, Gigli S, et al. Rifaximin improves clostridium difficile toxin A-induced toxicity in Caco-2 cells by the PXR-dependent TLR4/MyD88/NF-κB pathway. Front Pharmacol 2016; 7: 1–8
17. Wells CL, Westerlo E, Jechorek RP, Cytochalasin-induced actin disruption of polarized enterocytes can augment internalization of bacteria. Infect Immun 1998; 66: 2410–2419.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63.
19. Lessa FC, Mu Y, Bamberg WM, Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372: 825–834.
20. Lofgren ET, Cole SR, Weber DJ, Hospital-acquired Clostridium difficile infections: Estimating all-cause mortality and length of stay. Epidemiology 2014; 25: 570–575.
21. Just I, Wilm M, Selzer J, The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the rho proteins. J Biol Chem 1995; 270: 13932–13936.
22. Nusrat A, Madara JL, Parkos CA. Clostridium difficile toxins disrupt epithelial barrier function by altering membrane microdomain localization of tight junction proteins. Infect Immun 2001; 69: 1329–1336.
23. Gerhard R, Nottrott S, Schoentaube J, Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J Med Microbiol 2008; 57: 765–770.
24. Brito GAC, Fujji J, Carneiro-filho BA, Mechanism of Clostridium difficile toxin A – induced apoptosis in T84 cells. J Infect Dis 2002; 186: 1438–1447.
25. Esposito G, Ligresti A, Izzo A, The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. J Biol Chem 2002; 277: 50348–50354.
26. Scuderi C, Filippis D De, Iuvone T, et al. Cannabidiol in medicine: A review of its therapeutic potential in CNS disorders. Phytother Res 2009; 602: 597–602
27. Mechoulam R, Hanus L. Cannabidiol: An overview of some chemical and pharmacological aspects. Part I: Chemical aspects. Chem Phys Lipids 2002; 121: 35–43.
28. Bergamaschi MM, Queiroz RHC, Zuardi AW, Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011; 6: 237–249.
29. Hartsock A, Nelson WJ. Adherens and tight junctions: Structure, function and connections to the actin cytoskeleton. Biochim Biophys Acta 2008; 1778: 660–669.
30. Esposito G, Scuderi C, Valenza M, Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PloS One 2011; 6: e28668–e28668.
31. Frädrich C, Beer L-A, Gerhard R. Reactive oxygen species as additional determinants for cytotoxicity of Clostridium difficile Toxins A and B. Toxins 2016; 8: 1–12.
32. Kim JM, Kim JS, Jung HC, Differential expression and polarized secretion of CXC and CC chemokines by human intestinal epithelial cancer cell lines in Response to Clostridium difficile Toxin A. Microbiol Immunol 2002; 46: 333–342.
33. Aviello G, Romano B, Borrelli F, Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med 2012; 90: 925–934.
34. Capasso R, Borrelli F, Aviello G, Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Brit J Pharmacol 2008; 154: 1001–1008.
35. De Filippis D, Iuvone T, D’Amico A, Effect of cannabidiol on sepsis-induced motility disturbances in mice: Involvement of CB receptors and fatty acid amide hydrolase. Neurogastroenterol Motil 2008; 20: 919–927.